Disseminated Sclerosis
Conditions
Keywords
Multiple sclerosis, cognitive deterioration, biomarkers, cerebrospinal fluid, Alzheimer disease
Brief summary
In multiple sclerosis (MS) sub cortical cognitive impairments are frequently reported. Nevertheless, cortical cognitive troubles, with hippocampic memory troubles have been described. Besides inflammatory damage, early cortical and degenerative damage are well known. In neurodegenerative diseases, three biomarkers of the cerebro spinal fluid (CSF), reflecting lesional mechanisms, are measured: the beta amyloid peptide, the tau total protein, and the phospho tau protein. Preliminary studies shown increased level of tau in MS. No study compare cognitive impairment and biomarkers of CSF.The aim of this study is to measure in the CSF of MS patients these three biomarkers (beta amyloid peptide, tau total and phosphotau) in order to establish correlations between a profile of biomarkers and a pattern of cognitive troubles, cortical or subcortical.The possibility to show, in MS patients with memory hippocampic troubles, a profile of biomarkers closed from the one encountered in AD, could argue in support of the degenerative hypothesis in MS and lead to discuss the interest of the use of AD treatment in MS.
Interventions
OTHERCognitive impairment of multiple sclerosis
Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.
Sponsors
Nantes University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
17 Years to 66 Years
Healthy volunteers
No
Inclusion criteria
* Groups 1 and 2 -patients MS - EDSS\<7 Group 3- patients with first clinical inflammatory symptom
Exclusion criteria
* Pregnant or not taking contraceptive * Contraindication for lumbar puncture * Contraindication for NMR
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of this pilot study is to measure the level of total tau, phosphorylated tau and amyloid peptide in the CSF in order to establish correlations between a profile ofCSF biomarkers and a type of cognitive impairment, cortical or subcortical. | 15 months |
Secondary
| Measure | Time frame |
|---|---|
| To compare each biomarker individually between the three groups. | 15 months |
| To define clinical and paraclinical characteristics of MS patients with cortical cognitive dysfunction by a clinical and neuropsychological evaluation, a morphological (cerebral MRI) and a functional exam (cerebral scintigraphy). | 15 Months |
Countries
France
Outcome results
None listed